Hot Features
プレミアム
Lantern Pharma Inc (LTRN)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. 詳細を表示
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...
Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...
This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...
The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...
Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...
Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for...
Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.54 | 11.7391304348 | 4.6 | 5.3 | 4.34 | 73412 | 4.75986588 | CS |
| 4 | 1.03 | 25.0608272506 | 4.11 | 6.118 | 3.445 | 163114 | 4.95590972 | CS |
| 12 | 1.54 | 42.7777777778 | 3.6 | 6.118 | 2.79 | 104402 | 4.22467092 | CS |
| 26 | 1.49 | 40.8219178082 | 3.65 | 6.118 | 2.79 | 71543 | 4.06883999 | CS |
| 52 | 0.89 | 20.9411764706 | 4.25 | 11.99 | 2.79 | 136145 | 6.18184493 | CS |
| 156 | -1.4 | -21.4067278287 | 6.54 | 11.99 | 2.38 | 69395 | 5.7628257 | CS |
| 260 | -10.02 | -66.0949868074 | 15.16 | 24.84 | 2.38 | 75951 | 9.29251802 | CS |
Monksdream
5月前
anabu9
6月前
FALCON1
6月前
dinogreeves
9月前
Monksdream
9月前
Monksdream
10月前
dinogreeves
11月前
dinogreeves
11月前
spartex
11月前
Monksdream
11月前
dinogreeves
11月前
Monksdream
11月前
dinogreeves
11月前
dinogreeves
11月前
dinogreeves
11月前
Tremors!
11月前
Roily23
11月前
Roily23
11月前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
